Zentalis Pharmaceuticals, Inc. (ZNTL) Financials

ZNTL Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 253.1 million 70.4 million
Dec. 31, 2025 289.0 million 72.8 million
Sept. 30, 2025 327.3 million 74.4 million
June 30, 2025 351.7 million 77.2 million

ZNTL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -33.0 million 3.2 million
Dec. 31, 2025 -30.9 million 3.1 million
Sept. 30, 2025 -27.0 million 4.8 million
June 30, 2025 -34.7 million 6.3 million

ZNTL Net Income

No data available :(

ZNTL Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 211.8 million 34.7 million 34.7 million
Dec. 31, 2025 245.9 million - 35.7 million
Sept. 30, 2025 280.7 million - 36.7 million
June 30, 2025 303.4 million - 37.7 million

ZNTL Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 70.3 million
Dec. 31, 2025 71.7 million
Sept. 30, 2025 72.1 million
June 30, 2025 72.0 million

ZNTL Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 34000 28.7 million 9.0 million -151000
Dec. 31, 2025 - 29.5 million 7.9 million -
Sept. 30, 2025 - 23.0 million 10.8 million -
June 30, 2025 - 27.6 million 7.3 million -

ZNTL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 151000
Dec. 31, 2025 - 157000
Sept. 30, 2025 - -
June 30, 2025 - 160000

ZNTL

Price: $4.33

52 week price:
1.15
6.95

Earnings Per Share: -1.74 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 349136

Market Capitalization: 317.5 million

Links: